Compare MNKD & AWF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNKD | AWF |
|---|---|---|
| Founded | 1991 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.0M | 868.3M |
| IPO Year | 2004 | N/A |
| Metric | MNKD | AWF |
|---|---|---|
| Price | $3.52 | $10.29 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $8.69 | N/A |
| AVG Volume (30 Days) | ★ 6.3M | 604.1K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.57% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $348,966,000.00 | N/A |
| Revenue This Year | $35.81 | N/A |
| Revenue Next Year | $11.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.23 | $9.85 |
| 52 Week High | $6.51 | $11.43 |
| Indicator | MNKD | AWF |
|---|---|---|
| Relative Strength Index (RSI) | 64.71 | 52.40 |
| Support Level | $2.45 | $9.99 |
| Resistance Level | $6.08 | $10.58 |
| Average True Range (ATR) | 0.26 | 0.11 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 43.01 | 66.32 |
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Alliancebernstein Glb High Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its primary investment objective is to seek high current income, and secondarily, capital appreciation. The fund invests in debt securities, including Sovereign Debt Obligations and corporate debt, denominated in non-U.S. currencies as well as in the U.S. Dollar. It may invest without limit in emerging and developed markets and debt securities of U.S. and non-U.S. corporate issuers.